Invest Now
Samco Star Rating Ads

Indo US Bio-Tech Ltd Price Performance

  • Day's Low
  • ₹234.7
  • Day's High
  • ₹273
₹ 253.35
  • 52-w low
  • ₹222
  • 52-w high
  • ₹331.8
253.35
  • Day's open
    ₹234.7
  • Previous close
    ₹230.75
  • VWAP
    ₹257.78
  • Lower price band
    ₹202.7
  • Upper price band
    ₹304

Today's Market Action

The last traded share price of Indo US Bio-Tech Ltd was 253.35 up by 9.79% on the NSE. Its last traded stock price on BSE was 245.00 up by 5.60%. The total volume of shares on NSE and BSE combined was 19,157 shares. Its total combined turnover was Rs 0.49 crores.

Indo US Bio-Tech Ltd Medium and Long Term Market Action

Indo US Bio-Tech Ltd hit a 52-week high of 331.8 on 27-09-2024 and a 52-week low of 222 on 22-10-2024. The stock price of Indo US Bio-Tech Ltd is down by -0% over the last one month. Don't forget to check the full stock price history in the table below.

Indo US Bio-Tech Ltd Fundamentals

  • Market Cap (Cr): 508

  • Book Value (₹):

  • Stock P/E:

  • Revenue (Cr):

  • Total Debt (Cr):

  • Face Value (₹):

  • Roce (%):

  • ROE (%):

  • Earnings (Cr):

  • Promoter’s Holdings (%):

  • EPS (₹):

  • Debt to Equity:

  • Dividend Yield (%):

  • Cash (Cr):

Indo US Bio-Tech Ltd Mutual fund holdings and trends

FUND NAME Quantity Monthly Change (Qty)

Indo US Bio-Tech Ltd Shareholding Pattern

Similar Stocks

Company Price Market Cap (Cr) P/E

About Indo US Bio-Tech Ltd

Data not available.

Indo US Bio-Tech Ltd FAQ's

What is Share Price of Indo US Bio-Tech Ltd?

What is the Market Cap of Indo US Bio-Tech Ltd?

What is PE Ratio of Indo US Bio-Tech Ltd?

What is PB Ratio of Indo US Bio-Tech Ltd?

What is the CAGR of Indo US Bio-Tech Ltd?

How to Buy Indo US Bio-Tech Ltd Share?

Financials

(*All values are in Rs. Cr)
(*All values are in Rs. Cr)
(*All values are in Rs. Cr)
(*All values are in Rs. Cr)
(*All values are in Rs. Cr)

Consolidated Financial Performace In Graph(Net Profit)

Standalone Financial Performace In Graph(Net Profit)

(*All values are in Rs. Cr)

Consolidated Financial Performace In Graph(Net Profit)

Standalone Financial Performace In Graph(Net Profit)

(*All values are in Rs. Cr)

Consolidated Financial Performace In Graph(Cash Flow)

Standalone Financial Performace In Graph(Cash Flow)

News

Review

Pros

  • Above Average Sustainable RoE
    The company generates a sustainable return on equity greater than the expected cost of capital which implies that the underlying business can create and compound value over a period time due to it's ability to generate above average return on capital.
  • Asset Light Business
    The company operates a great asset light business with a high Asset turnover ratio of 7.52. A high asset turnover ratio is a great driver of RoE and can improve shareholder returns. A relatively higher asset turnover ratio also will result in lower dilution as the business grows its revenues as earnings.

Cons

  • Low Return on Capital Employed
    The company is unable to generate sufficient return on capital employed which impairs it's ability to generate high return for shareholders after accounting for taxes, interest and other non-equity stakeholders.
  • Poor Cash Flow Conversion
    The business has very poor cash conversion ratio of only -41.67% of operating earnings getting converted into operating cash flow. This implies that increase in profits has not translated into higher cash flows for the business and incrementally higher investments in working capital which works negatively for shareholders.
  • Low Interest Coverage
    The company has a very low Interest coverage ratio of 5.50 times which implies that a large portion of operating profits are getting attributed to payment of interest to debtholders. This leaves lower earnings and cash flows for equity shareholders which is negative for returns.
  • Highly Cyclical Industry
    The company operates an extremely cyclical business with unpredictable earnings and cash flows. This shall result in very high stock price volatility and returns which would negatively impact shareholder returns.
  • Poor Capital Allocation
    The company has disproportionately high amount of assets locked up in working capital, cash and cash equivalents, loans and advances, etc to the extent of 87.50 % of total assets. This reflects poorly on the capital allocation strategy of the management which negatively impacts shareholder returns.
  • Poor Working Capital Cycle
    The company has a very poor working capital cycle of 366 days which requires very high investments in working capital. This reduces free cash flow generation for the business and negatively impacts shareholder value and returns.
  • Poor Corporate Governance
    The general corporate governance standards of the company are poor which can negatively impact shareholder value and returns.

Valuation Analysis

Margin of safety
(17/11/2024)
Stock Valuation
Dark green line
111
0.00%
0.00% People are bullish about Indo US Bio-Tech Ltd
100.00%
100.00 % People are bearish about Indo US Bio-Tech Ltd

What is your opinion about this Stock?

Historical Data

Samco Star Rating Ads

Indo US Bio-Tech Ltd

253.35 +22.60 (9.79%)

Brokerage & Taxes at Samco

Brokerage & Taxes at Other traditional broker

Potential Brokerage Savings with Samco ₹ 49.62()

Top Gainers (NIFTY 50)

Stock Name Change %

    Top Losers (NIFTY 50)

    Stock Name Change %

      Open Free Account Now
      Open a Demat Account

      Free Trading & Demat Account

      +91